Zura Bio (NASDAQ:ZURA) Coverage Initiated at Piper Sandler

Piper Sandler started coverage on shares of Zura Bio (NASDAQ:ZURA) in a research report sent to investors on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $26.00 price target on the stock.

Separately, Oppenheimer reaffirmed an outperform rating and set a $16.00 price target (down previously from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Zura Bio presently has a consensus rating of Buy and a consensus target price of $18.00.

Zura Bio Stock Up 1.5 %

NASDAQ ZURA opened at $4.69 on Friday. Zura Bio has a 12-month low of $2.00 and a 12-month high of $14.00. The company has a fifty day simple moving average of $3.28 and a two-hundred day simple moving average of $3.92.

Insider Activity at Zura Bio

In related news, Director Amit Munshi purchased 159,744 shares of the business’s stock in a transaction on Monday, April 22nd. The shares were bought at an average cost of $3.13 per share, with a total value of $499,998.72. Following the transaction, the director now owns 777,384 shares of the company’s stock, valued at $2,433,211.92. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired 170,926 shares of company stock worth $534,998 over the last three months. Company insiders own 15.80% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

Hedge funds have recently bought and sold shares of the stock. Forefront Analytics LLC increased its holdings in shares of Zura Bio by 46.8% during the 4th quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock valued at $99,000 after purchasing an additional 6,765 shares in the last quarter. Raymond James & Associates increased its holdings in Zura Bio by 14.0% in the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock valued at $511,000 after buying an additional 9,481 shares in the last quarter. Lynx1 Capital Management LP purchased a new position in Zura Bio in the third quarter valued at $65,000. Bank of New York Mellon Corp acquired a new position in shares of Zura Bio in the third quarter worth about $224,000. Finally, Eisler Capital US LLC purchased a new stake in shares of Zura Bio during the 3rd quarter worth about $660,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.